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AsBACKGROUND Evidence is lacking about the effectiveness of risk reduction interventions in patients with asymp-
tomatic peripheral arterial disease.
OBJECTIVES This study aimed to assess whether statin therapy was associated with a reduction in major adverse
cardiovascular events (MACE) and mortality in this population.
METHODS Data were obtained from 2006 through 2013 from the Catalan primary care system’s clinical records
database (SIDIAP). Patients age 35 to 85 years with an ankle-brachial index #0.95 and without clinically recognized
cardiovascular disease (CVD) were included. Participants were categorized as statins nonusers or new-users (ﬁrst
prescription or represcribed after at least 6 months) and matched 1:1 by inclusion date and propensity score for statin
treatment. Conditional Cox proportional hazards modeling was used to compare the groups for the incidence of MACE
(myocardial infarction, cardiac revascularization, and ischemic stroke) and all-cause mortality.
RESULTS The matched-pair cohort included 5,480 patients (mean age 67 years; 44% women) treated/nontreated
with statins. The 10-year coronary heart disease risk was low (median: 6.9%). Median follow-up was 3.6 years. Inci-
dence of MACE was 19.7 and 24.7 events per 1,000 person-years in statin new-users and nonusers, respectively. Total
mortality rates also differed: 24.8 versus 30.3 per 1,000 person-years, respectively. Hazards ratios were 0.80 for
MACE and 0.81 for overall mortality. The 1-year number needed to treat was 200 for MACE and 239 for all-cause
mortality.
CONCLUSIONS Statin therapy was associated with a reduction in MACE and all-cause mortality among participants
without clinical CVD but with asymptomatic peripheral arterial disease, regardless of its low CVD risk. The absolute
reduction was comparable to that achieved in secondary prevention. (J Am Coll Cardiol 2016;67:630–40)
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AND ACRONYM S
ABI = ankle-brachial index
CHD = coronary heart disease
GP = general practitioner
MACE = major adverse
cardiovascular event
NNT = number needed to treat
PAD = peripheral arterial
disease
PS = propensity score
RCT = randomized clinical trial
SIDIAPQ = The Information
System for the Development of
Research in Primary Care,
tyP rescription of statins to prevent cardiovasculardisease (CVD) is mainly a “high-risk” strategyfocused on detection and intensive manage-
ment of risk factors in individuals with a high proba-
bility of developing CVD (1). In the lipid management
arena, this approach is grounded in the knowledge
that the absolute risk reduction achieved with statin
therapy improves with increasing CVD risk (2).
Detection of asymptomatic peripheral arterial dis-
ease (PAD) using the ankle-brachial index (ABI) in
screening procedures is a potentially useful strategy
to identify candidates for intensive risk-factor man-
agement (3) because low ABI values are associated
with an increased risk of CVD and total mortality,
independent of the CVD risk calculated by the Fra-
mingham function (4). Moreover, ABI measurement is
reliable, simple, and inexpensive, and therefore
suitable for target-population risk screening (5).SEE PAGE 641Unfortunately, the usefulness of this screening
remains uncertain (6,7), and available guidelines
offer heterogeneous recommendations (8). The
American College of Cardiology, American Heart
Association, and Inter-Society Consensus for the
management of patients with PAD have recom-
mended ABI screening, especially for certain groups
of asymptomatic individuals (principally subjects age
50 to 69 years who also have diabetes or smoking
history, and all patients age >70 years) (9). In
contrast, the U.S. Preventive Services Task Force
recommends against routine ABI screening in
asymptomatic adults (8). One fundamental reason for
this uncertainty is the lack of evidence about the
effectiveness of risk reduction interventions when
asymptomatic PAD is detected (10).
In this study, we aimed to assess whether statin
use was associated with a reduction in incidence of
CVD and mortality in individuals with asymptomatic
PAD detected by ABI measurement.
METHODS
DATA SOURCE. The Information System for the
Development of Research in Primary Care (SIDIAP)
was created by the Catalan Institute of Health and the
Jordi Gol Primary Care Research Institute. This ano-
nymized database contains standardized, cumulated,authors have reported that they have no relationships relevant to the conte
contributed equally to this work.
Manuscript received October 30, 2015; accepted November 3, 2015.clinical information about nearly 5 million
patients attended by the 3,414 general prac-
titioners (GPs) in the 274 primary care prac-
tices managed by the Catalan Institute of
Health, consisting of approximately 80% of
the Catalan population or 10% of the Spanish
population (11). The records include de-
mographic data; clinical diagnoses coded by
International Classiﬁcation of Diseases, 10th
revision; referral and hospital discharge in-
formation (International Classiﬁcation of
Diseases-9th revision); laboratory tests; and
treatments (drug prescriptions and drugs
invoiced at any community pharmacy). All
GPs follow the same clinical protocols for
data recording, and completeness and conti-
nuity are assessed externally. A subset of records
from GPs who surpass pre-deﬁned data quality stan-
dards (12) constitute The Information System for the
Development of Research in Primary Care, Quality
(SIDIAPQ), which provides anonymized data on
approximately 2 million patients, attended by 1,365
GPs, yielding nearly 14 million person-years of clin-
ical data for 2005 through 2013. The high quality of
these data and its representativeness of the popula-
tion of Catalonia in terms of geographic, age, and sex
distributions has been previously documented (12),
speciﬁcally for CVD and cardiovascular risk factors
(13). Ethics approval for observational research
using SIDIAPQ data was obtained from a local ethics
committee.
PARTICIPANTS AND STUDY DESIGN. A cohort study
was designed for matched-pair analysis on the basis
of study inclusion date and propensity score (PS) for
statin treatment. All patients age 35 to 85 years with
an ABI measurement recorded in SIDIAPQ between
April 2006 and December 2011 were eligible for in-
clusion. Follow-up lasted till December 2013, guar-
anteeing at least 2 years of data for each participant.
Although individuals with an ABI between 0.91 and
0.95 can be considered to be at “borderline” cardio-
vascular risk (14), we used an ABI of #0.95 instead of
0.90 to identify individuals with asymptomatic PAD,
as in a previous clinical trial with aspirin (15). This
choice was made because the 0.95 cut-point covered a
wider proportion of the population (16), with notably
higher risk than patients with ABI between 1 and
Qualints of this paper to disclose. Drs. Ramos and Garcia
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ABI >1.4 (6.5% of those with an ABI measurement)
could present with arterial obstruction, they were
excluded from analysis because toe-brachial index
measurements were not available to discard or
conﬁrm the diagnosis.
All ABI measurements were performed during
outpatient examinations by each participant’s GP in
the primary care setting. For patients with more than
1 ABI measurement, the analysis used the ﬁrst one
taken. Exclusion criteria were any previous history of
symptomatic PAD, coronary heart disease (CHD),
stroke, or revascularization procedures. Symptomatic
PADwas speciﬁcally ruled out by excluding: 1) patients
with any primary care or hospital discharge diagnosis
code suggesting clinically recognized PAD; 2) patients
with any symptom of intermittent claudication
detected by thorough revision of uncoded information
(GP’s free text notes); 3) patients who had been pre-
scribed any drug related to intermittent claudication
(cilostazol, pentoxifylline, buﬂomedil, or nafti-
drofuryl); and 4) patients with an ABI<0.4, even in the
absence of any suggestive symptom.
STATIN EXPOSURE. To prevent survivor bias and
covariate measurement bias, a “new-users design”
was selected over prevalent statin users (17).
New-users were deﬁned as receiving statins (i.e.,
simvastatin, pravastatin, lovastatin, ﬂuvastatin,
rosuvastatin, or atorvastatin) for the ﬁrst time or after
a hiatus of at least 6 months. The date of this new
statin prescription was considered the index date. In
descriptive analysis, we classiﬁed patients’ statins
exposure according to the drug’s cholesterol reduc-
tion capacity as follows: low, <30%; moderate, 30% to
40%; high, 40% to 50%; and very high, >50% (18).
FOLLOW-UP AND OUTCOMES. Onset of vascular
diseases during follow-up was identiﬁed from rele-
vant SIDIAPQ codes in both primary care and hospital
discharge records. Primary outcomes were total
mortality and major adverse cardiovascular event
(MACE), a composite of hard CHD (myocardial
infarction, cardiac revascularization, or coronary
death) and stroke (fatal and nonfatal ischemic
stroke). We also considered angina and coronary
heart disease (a composite of angina and hard CHD) as
secondary outcomes. Follow-up continued until the
earliest date of a primary outcome, transfer out of the
SIDIAPQ database Catalan reference area, death, or
censoring on December 31, 2011.
ADVERSE EFFECTS. Liver toxicity and myopathy
were considered attributable to statins if they
occurred within 12 months of initiating treatment.
New-onset diabetes, cancer, and hemorrhagic strokewere considered more likely to be associated with
long-term use, and thus were attributed to statins if
the diagnosis occurred after 1 year (19).
DATA EXTRACTION RELATING TO POTENTIAL
CONFOUNDERS. We explored the variables associ-
ated with statin prescription to determine candidate
variables for the statin treatment PS. The following
were obtained from SIDIAPQ: age, sex, systolic and
diastolic blood pressure, body mass index, vascular
risk factors (diabetes mellitus, hypertension, hyper-
cholesterolemia, smoking, and high alcohol con-
sumption), other comorbidities at baseline (atrial
ﬁbrillation, lupus, arthritis, asthma, chronic obstruc-
tive pulmonary disease, hypothyroidism, depres-
sion, and cancer), other medication (nonstatin
lipid-lowering drugs, diuretic agents, beta-blockers,
calcium-channel blockers, angiotensin-converting
enzyme inhibitors, antidiabetic agents, psycho-
analeptics, psycholeptics, anti-inﬂammatory drugs,
aspirin, and oral corticosteroids), and laboratory tests
(total cholesterol, low-density lipoprotein [LDL]
cholesterol, high-density lipoprotein cholesterol, tri-
glycerides, glucose, glycosylated hemoglobin, and
glomerular ﬁltration rate). For each participant, we
also recorded a quality score for the GP’s clinical
practice derived from standard external evaluation
procedures and a deprivation index (MEDEA index)
(20). The CHD risk was calculated using the Framing-
ham function adapted to the Spanish population, duly
validated (21).
STATISTICAL ANALYSES. Categorical variables are
presented as percentages and continuous variables as
mean  SD or median (1st and 3rd quartiles), both
with 95% conﬁdence intervals (CIs) when required.
Validity of ABI measures was assessed by estimating
the intraclass correlation coefﬁcient of the SIDIAPQ
ABI measure with that recorded for the 134 patients
who had also participated in a local epidemiological
survey that used standardized measurement methods
(16).
We used 10 multiple imputations by chained
equations (22) to replace missing baseline values
for total cholesterol, high-density lipoprotein
cholesterol, triglycerides, glucose, systolic and dia-
stolic blood pressure, body mass index, and MEDEA
deprivation index. In addition to incorporating
the missing-at-random assumption, we compared
complete-case only results with the multiple impu-
tation as a sensitivity analysis.
Because of nonrandom treatment allocation, a
logistic model on the basis of confounding covariates
was used to calculate a statin therapy PS. Maximum
cardinality matching of new-users and nonusers was
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633performed on a weighted bipartite graph on the basis
of PS (to avoid confounding by indication bias) and on
prescription time distribution (to avoid immortal time
bias [23]). Matching was 1:1 within a caliper of one-
quarter of the PS SD. Adequacy of matching was
assessed by estimating the standardized differences
between statin new-users and nonusers for all
variables.
The hazard ratios of statin exposure were calcu-
lated for outcome events using conditional Cox
proportional hazard regression models, and pro-
portionality of hazards assumption was tested.
Additional regression adjustments were performed
after PS matching to prevent residual confounding in
a sensitivity analysis. Variables not sufﬁciently
balanced after PS matching and those associated with
a worse prognosis were also included in the models.
Absolute risk reductions and 1-year number neededFIGURE 1 Study Flow Chart
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Participant selection in the study. ABI ¼ ankle brachial index; CVD ¼ card
of Research in Primary Care.to treat (NNT) for 1 additional patient to survive to
this speciﬁc time point were calculated. We also
carried out sensitivity analysis considering the
exposure to statins as a time-varying covariate and
compared the results with the intention-to-treat
approach. Statistical analyses used R software
version 3.2 (R Foundation for Statistical Computing,
Vienna, Austria) (24,25).
RESULTS
During the study period, an ABI measurement was
recorded in the SIDIAPQ database for 74,280 in-
dividuals. Of these, 12,119 fulﬁlled all inclusion
criteria and 3,329 initiated statin therapy during the
study period. The study included 5,480 participants
(2,740 statin new-users and 2,740 control subjects)
matched by PS and inclusion date. The study ﬂowmeasurement
eriod in SIDIAP
ase
ndividuals)
et inclusion criteria
s in this period
s in this period
re and Index
tching
2,740 statin non users
19 transferred from SIDIAP
and censored its follow up
iovascular disease; SIDIAP ¼ Information System for the Development
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634chart is detailed in Figure 1. Median follow-up was
3.6 years (1st and 3rd quartiles, 4.9 and 7.8). Only
12 participants in the statin group and 19 in the non-
statin group were lost to follow-up; all of them
transferred out of the SIDIAPQ reference area and
were censored at their transfer date.
The proportion of missing data for incomplete
variables and a comparison of the complete-case
dataset and imputed dataset are shown in Online
Table 1. The mean values of these variables
remained similar after multiple imputations. The
proportion of statin users matched with nonusers was
82.3% (Online Figure 1), and no signiﬁcant clinical
differences between matched and unmatched
individuals were observed, although unmatched
individuals were slightly younger, had a slightly
lower CHD risk proﬁle, and were less hyperlipidemic
(Online Table 2).
Baseline characteristics for statin new-users and
nonusers before and after PS matching are presented
in Table 1. No signiﬁcantly or clinically relevant
standardized differences were observed. Women
constituted 44% of both cohorts and the mean age
was 67.2  11.0 years. Diabetes was present in nearly
72% of participants, hypertension in 75%, smoking in
29%, and hypercholesterolemia in 56%; nonetheless,
median 10-year CHD risk was low, at 6.9% (1st and 3rd
quartiles, 3.9% and 11.9%), as expected in a Mediter-
ranean country (26). Over 75% of new-users were
treated with a statin of low and moderate LDL-
reduction capacity (Table 1). The ABI measurements
registered in SIDIAPQ presented an intraclass corre-
lation coefﬁcient of 0.75 (95% CI: 0.62 to 0.84) with
the 134 participants for whom an ABI measurement
under standardized methods was available from an
epidemiological study.
EFFECTIVENESS ENDPOINTS. A ﬁrst MACE occurred
in 201 and 245 participants, and death in 263 and
316 participants, in the new-users and nonusers
groups, respectively.
Differences were observed in MACE and all-cause
mortality rates (in events per 1,000 person-years):
19.7 (95% CI: 17.2 to 22.5) in new-users versus 24.7
(95% CI: 21.8 to 27.8) in nonusers (Figure 2) and 24.8
(95% CI: 22.0 to 27.8) in new-users versus 30.3 (95% CI:
27.2 to 33.6) in nonusers, respectively. Hazard ratios
for primary endpoint events signiﬁcantly differed be-
tween groups (Table 2). MACE decreased relatively by
20% (95%CI: 3% to 34%) and all-causemortality by 19%
(95% CI: 3% to 32%). The 1-year NNTs were for 200
MACE and 239 for all-cause mortality.
Comparisons of NNT with statins to prevent 1 event
(MACE and all-cause mortality) during follow-up areshown in the Central Illustration by ABI cut-points and
10-year CHD risk categories. Brieﬂy, NNT decreased
with ABI cut-point.
The complete-case analysis showed no statistical
or clinically relevant differences from the hazard ra-
tios obtained in previously described analyses of the
multiple imputations dataset (Online Table 3). Hazard
ratios from the model with additional adjustment for
hypertension, hypercholesterolemia, aspirin use,
nonstatin lipid-lowering drug use, ABI, and 10-year
coronary heart disease risk did not signiﬁcantly differ
from the PS matching model (Online Table 4). The
hazard ratios obtained when considering statins as a
time-varying covariate did not signiﬁcantly differ
from those of the intention-to-treat approach; the
relative differences were <10% for all outcomes
(Online Table 5). We observed no signiﬁcant increase
of adverse events attributable to statins (Table 2).
DISCUSSION
To our knowledge, this is the ﬁrst study to report the
association between statins and both MACE and
mortality reduction among individuals free of clinical
CVD, but with asymptomatic PAD identiﬁed by ABI.
This reduction was observed regardless of 10-year
CHD risk levels at baseline, which for most partici-
pants were well below the treatment threshold
according to current prevention guidelines (27).
Statin treatment produced an absolute reduction in
MACE of about 5 per 1,000 individuals/year and in
overall mortality of over 4 per 1,000 individuals/year.
The absolute reduction in both MACE and all-cause
mortality was notably higher than that reported in
individuals at low risk in randomized clinical trials
(RCTs) (28) and was comparable to that achieved in
secondary prevention (29) or in individuals with
symptomatic PAD (30). This is consistent with the
idea that asymptomatic PAD (diagnosed through
screening) and symptomatic PAD are associated with
vascular events and mortality to a similar extent (31).
Furthermore, we observed that the degree of limb
obstruction, estimated by the ABI value, was associ-
ated with noticeable changes in NNT, whereas
changes in 10-year CHD risk produced no substantial
effect, except for those individuals with 10-year CHD
risk of #10%, in which case the NNT increased. This
could suggest that the ABI value better predicts the
beneﬁt of statins than does the estimated risk on the
basis of CVD risk charts (Central Illustration) in this
population.
Our study results have 2 major implications. First,
in the absence of clinically recognized CVD, asymp-
tomatic ABI #0.95 might be sufﬁcient to indicate
TABLE 1 Characteristics of Participants in Statin New-User and Nonuser Groups Before and After Propensity Score Matching
Before Propensity Score Matching After Propensity Score Matching
Statin New-Users
(n ¼ 3,329)
Statin Nonusers
(n ¼ 8,790)
Standardized
Difference
Statin New-Users
(n ¼ 2,740)
Statin Nonusers
(n ¼ 2,740)
Standardized
Difference
Age, yrs 66.7  10.7 66.2  12.5 0.043 66.9  10.7 67.5  11.2 0.061
Male 1,892 (56.8) 4,851 (55.2) 0.033 1,532 (55.9) 1,538 (56.2) 0.004
ABI 0.80  0.14 0.82  0.12 0.211 0.80  0.14 0.81  0.13 0.014
Smokers 1,027 (30.9) 2,294 (26.1) 0.105 801 (29.3) 798 (29.2) 0.002
Diabetes 2,434 (73.1) 5,670 (64.5) 0.187 1,983 (72.4) 1,977 (72.2) 0.005
Hypertension 2,528 (75.9) 5,909 (67.2) 0.194 2,042 (74.6) 2,077 (75.8) 0.029
Hypercholesterolemia 2,062 (61.9) 2,491 (28.3) 0.717 1,516 (55.4) 1,543 (56.4) 0.020
Obesity 1,616 (48.6) 4,210 (47.9) 0.013 1,347 (49.2) 1,355 (49.5) 0.006
Body mass index, kg/m2 29.8  5.3 29.6  5.4 0.038 29.9  5.4 29.9  5.2 0.002
Blood pressure
Systolic, mm Hg 138.0  17.0 137.0  17.5 0.056 137.9  17.0 137.6  17.3 0.015
Diastolic, mm Hg 76.6  10.1 76.6  9.9 0.003 76.5  10.1 76.4  9.8 0.012
Total cholesterol, mg/dl 219.2  38.0 197.0  34.3 0.613 213.7  35.5 213.4  34.4 0.010
LDL cholesterol, mg/dl 137.1  32.9 119.3  29.1 0.573 132.5  30.7 132.5  29.5 0.002
HDL cholesterol, mg/dl 51.6  13.9 52.6  14.7 0.070 51.7  14.0 51.5  13.9 0.016
Serum triglycerides, mg/dl 158.5  97.6 137.6  90.8 0.222 154.0  93.6 155.5  108.3 0.014
Glycosylated hemoglobin, %* 7.4  1.7 7.2  1.6 0.061 7.4  1.7 7.3  1.7 0.003
Medication
Aspirin 1,386 (41.6) 1,674 (19.0) 0.507 990 (36.2) 954 (34.9) 0.028
Diuretic 642 (19.3) 1,620 (18.4) 0.022 534 (19.5) 528 (19.3) 0.006
Beta-blocker 346 (10.4) 797 (9.0) 0.050 286 (10.4) 288 (10.5) 0.003
ACE inhibitor/ARB 1,646 (49.4) 3,389 (38.6) 0.221 1,283 (46.9) 1,289 (47.1) 0.004
Calcium-channel blocker 508 (15.3) 1,005 (11.4) 0.113 393 (14.4) 404 (14.8) 0.011
Nonstatin lipid lowering 246 (7.4) 470 (5.4) 0.084 197 (7.2) 215 (7.9) 0.025
Anti-inﬂammatory drugs 852 (25.6) 2,081 (23.7) 0.045 682 (24.9) 684 (25.0) 0.002
Antidiabetic therapy 1,752 (52.6) 3,699 (42.1) 0.212 1,391 (50.8) 1,371 (50.1) 0.015
Statin by LDL reduction capacity
Low (<30%) 98 (2.9) — — 80 (2.9) — —
Moderate (30%–40%) 2,449 (73.6) — — 2,042 (74.6) — —
High (40%–50%) 736 (22.1) — — 580 (21.2) — —
Very high (>50%) 36 (1.1) — — 28 (1.0) — —
10-yr CHD risk 9.13  6.7 7.37  6.1 0.274 8.8  6.5 8.9  6.8 0.012
Comorbidities
Atrial ﬁbrillation 207 (6.2) 519 (5.9) 0.013 177 (6.5) 182 (6.6) 0.006
CKD 572 (17.2) 1,251 (14.2) 0.034 467 (17.0) 465 (17.0) 0.001
COPD 393 (11.8) 955 (10.9) 0.030 316 (11.6) 329 (12.0) 0.014
Arthritis 24 (0.7) 79 (0.9) 0.020 22 (0.8) 26 (0.8) 0.006
Asthma 117 (3.5) 316 (3.6) 0.004 97 (3.6) 101 (3.7) 0.007
Cancer 598 (18.0) 1,545 (17.6) 0.010 495 (18.1) 515 (18.8) 0.019
Hypothyroidism 233 (6.8) 564 (6.4) 0.023 193 (7.1) 203 (7.4) 0.014
Depression 107 (3.2) 252 (2.9) 0.020 86 (3.2) 83 (3.1) 0.005
Number of visits 6.4  7.0 6.1  6.9 0.054 6.2  7.0 6.3  7.0 0.013
Socioeconomic status
1 (most deprived) 638 (19.2) 1,788 (20.3) 0.029 559 (20.4) 541 (19.8) 0.016
2 624 (18.8) 1,801 (20.5) 0.044 530 (19.4) 563 (20.6) 0.030
3 656 (19.7) 1,765 (20.1) 0.009 541 (19.8) 552 (20.2) 0.010
4 687 (20.7) 1,735 (19.8) 0.023 552 (20.2) 542 (19.8) 0.009
5 (less deprived) 721 (21.7) 1,699 (19.3) 0.058 555 (20.3) 538 (19.7) 0.016
Values are mean  SD or n (%). *Calculated for all participants with diabetes mellitus.
ABI ¼ ankle brachial index; ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; CHD ¼ coronary heart disease; COPD ¼ chronic obstructive pulmonary disease;
CKD ¼ chronic kidney disease (glomerular ﬁltration rate <60 ml/min/1.73 m2); HDL ¼ high-density lipoprotein; LDL ¼ low-density lipoprotein.
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FIGURE 2 Survival Cox Model
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636statin use independently of the risk estimated
by risk functions. Recent American College of Cardi-
ology/American Heart Association guidelines on the
treatment of blood cholesterol to reduce atheroscle-
rotic cardiovascular risk in adults suggest that ABI can
be assessed as an additional factor to support statin
therapy in patients at low 10-year coronary heart
disease risk and with moderate LDL cholesterol blood
level (27). Our results support such a strategy,TABLE 2 Hazard Ratios of Incident Cardiovascular Events and Mortali
Use of Statins: Intention-to-Treat Analysis
Statin New-Users
Events
Incidence Rate*
(95% CI)
Outcomes of interest
Hard coronary heart disease 88 8.4 (6.8–10.4)
Angina 68 6.5 (5.1–8.2)
Coronary heart disease 123 11.9 (9.9–14.2)
Stroke 123 11.8 (9.9–14.1)
Major cardiovascular event 201 19.7 (17.2–22.5)
All-cause mortality 263 24.8 (22.0–27.8)
Adverse effects
Cancer 154 22.2 (18.9–25.8)
Hemorrhagic stroke 37 4.7 (3.3–6.5)
Diabetes 82 34.8 (27.9–42.6)
Hepatotoxicity 3 —
Myopathy 3 —
*Per 1,000 person-years.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; NNT ¼ number needed to treat.because most patients in our study meet these
characteristics.
Second, and consequently, routine ABI screening
for asymptomatic PAD in the targeted population
could be a useful strategy (32) to identify candidates
for statin therapy, most of whom would not be
considered candidates solely on the basis of risk
functions (16). A targeted population ABI screening
could detect up to 85% of those individuals withty and the 1-Year Number Needed to Treat to Prevent 1 Event by the
Statin Nonusers
HR
(95% CI) NNTEvents
Incidence Rate*
(95% CI)
124 12.2 (10.2–14.5) 0.70 (0.52–0.94) 276
85 8.3 (6.7–10.2) 0.89 (0.69–1.16) —
162 16.1 (13.8–18.7) 0.74 ( 0.58–0.95) 233
134 13.2 (11.1–15.6) 0.77 (0.54–1.12) —
245 24.7 (21.8–27.8) 0.80 (0.66–0.97) 200
316 30.3 (27.2–33.6) 0.81 (0.68–0.97) 239
140 20.6 (17.4–24.2) 1.08 (0.82–1.39) —
36 4.7 (3.3–6.5) 1.01 (0.61–1.68) —
68 30.3 (23.7–38.0) 1.16 (0.80–1.69) —
1 — — —
2 — — —
CENTRAL ILLUSTRATION Statins and Asymptomatic Low Ankle Brachial Index: Number Needed to Treat
A
B
Ramos, R. et al. J Am Coll Cardiol. 2016; 67(6):630–40.
The number needed to treat to prevent 1 event over a 5-year follow-up by ankle brachial index (A) and by coronary heart disease risk at baseline (B).
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637asymptomatic PAD (32). Patient characteristics
in our study are similar to those observed in
population-based studies of patients with low ABI
(32,33), and could represent 5% to 17% of the general
population, depending on age group (16,32,33).
These results, on the basis of observational data,
may not provide enough evidence to establish clinicalrecommendations, but they do justify the perfor-
mance of RCTs to further elucidate this question.
ADVERSE EFFECTS. No excess risk of serious adverse
effects attributable to statin use was observed during
follow-up. Excess risks of myopathy or liver toxicity
were also absent among statins new-users. Although
new-users presented a higher incidence of new
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638diabetes than nonusers (hazard ratio: 1.14), the
difference was not signiﬁcant. Limited statistical po-
wer might explain these results because there is evi-
dence that statins slightly increase the incidence of
new-onset diabetes (34). However, diabetes (35),
myopathy (36), and hepatopathy (37) are more
frequent in intensive regimens; in our study,
approximately 80% of statin treatments were low-to
medium-potency regimens. We also have to consider
that mild myopathy or mild hepatopathy might be
underestimated in electronic medical records.
We also observed no increased risk of cancer or
hemorrhagic stroke among statins new-users, which
is consistent with previous studies (38,39). We cannot
discard the possibility that the incidence of diabetes,
cancer, or hemorrhagic stroke could increase in this
population with longer statin exposure.
STUDY CHARACTERISTICS THAT MERIT CONSIDERATION.
When data are collected in well-designed, qual-
ity-assured databases and analyzed using appropriate
methods, electronic medical records offer an
outstanding opportunity to answer relevant ques-
tions related to medical treatments’ effectiveness,
close to actual clinical practice, and at a reasonable
cost (40). This electronic database approach probably
will be a noteworthy aspect of modern epidemiology
in this 21st century (41). Researchers have demon-
strated that such studies properly replicate the effects
of statins observed in RCTs (42); it also has been
suggested that observational studies could tend to
overestimate the effect size of interventions (43) if
several key points are not well addressed. First, a
matching algorithm might fail to capture a broadly
representative population. In our case, matched in-
dividuals were very similar to those who were not
matched (Online Table 2, Online Figure 1) and also to
those with low ABI in population-based epidemio-
logical studies in the same population (32,33). The
exception is the proportion of diabetes (twice as high
in our study), which is probably due to diabetes
guidelines strongly recommending ABI screening
(44). We cannot discard that this might affect our
results to some extent, but the general characteristics
of our study participants support their representa-
tiveness of the asymptomatic PAD population, which
provides external validity for targeted population
screening (32).
Second, low data quality could generate misclassi-
ﬁcation. In this study, the presence of cardiovascular
risk factors and outcomes were previously validated in
SIDIAP (13), and the validity of ABI measurement was
veriﬁed in a subgroup of 134 participants. Moreover,
the validity of statin exposure in the medical records
was conﬁrmed by the ofﬁcial invoicing records fromcommunity pharmacies. Nevertheless, we cannot
exclude some degree of under-reporting of outcomes,
which could lead to a nondifferentialmisclassiﬁcation;
this would reduce statistical power, biasing results
toward the null hypothesis.
Third, confounding indications can produce bias in
observational studies. We used a new-users design
to estimate confounding factors and then matched
new-users with nonusers by PS and index date. The
exposed (new-users) group was comparable with the
nonexposed (nonusers) group for all relevant vari-
ables (Table 2). Furthermore, the hazard ratios
obtained in a model with additional adjustments for
relevant covariates did not vary signiﬁcantly from the
PS matching model. However, relative effect sizes of
statins observed in our study were remarkably similar
to those reported in RCTs, suggesting that we suc-
ceeded in overcoming potential confounders (28,29).
Fourth, the presence of missing data can inﬂuence
the results. In our study, missing values did not
exceed 30% for any variable, and the characteristics
of the complete-case analysis did not differ from
imputed data (Online Table 1) nor from individuals
who also participated in a previous epidemiological
study (32,33).
Fifth, immortal time bias can arise when the
determination of an individual’s treatment status
involves a delay or waiting period during which, by
design, death or the study outcome cannot be
analyzed. To prevent this potential bias, in addition
to PS we used prescription time-distribution match-
ing (23). With this method, the overall distribution of
the nonusers index date is matched to that of the
users’ time of ﬁrst prescription. This prevents the
imbalance of prescription time distribution between
the 2 groups, which can generate a survival bias (23).
Sixth, discrepancies may occur when comparing
statins as a time-varying covariate with the
“intention-to-treat” approach. In the present study,
this comparison yielded no signiﬁcant differences.
If these results are conﬁrmed, they could easily be
applied in clinical practice and have a large effect
on CVD prevention, because a non-negligible 5% to
17% of individuals have the characteristics reported
here (16,32,33). Medical prescriptions in primary
prevention account for part of the increasing eco-
nomic burden of CVD in developed countries, so this
strategy could be focused on actual high-risk in-
dividuals, ensuring cost-effectiveness (45). Our re-
sults on the basis of data from daily medical practice
suggest this approach. Longer-term RCTs are needed
to conﬁrm our ﬁndings. Reliable cost-effectiveness
estimates for the ABI screening strategy should also
be obtained.
PERSPECTIVES
COMPETENCY IN SYSTEMS-BASED PRACTICE: Regardless
of other risk factors and in the absence of a clinical history of
CVD, statin therapy in patients with asymptomatic PAD is asso-
ciated with a reduction in MACE and all-cause mortality. The
absolute risk reduction is comparable to that achieved in sec-
ondary prevention settings.
TRANSLATIONAL OUTLOOK: Prospective clinical trials
should address the utility of systematic screening for PAD and
implementation of statin therapy on the basis of measurement of
the ABI alone as a population-based strategy for prevention of
fatal and nonfatal cardiovascular events.
J A C C V O L . 6 7 , N O . 6 , 2 0 1 6 Ramos et al.
F E B R U A R Y 1 6 , 2 0 1 6 : 6 3 0 – 4 0 ABI, Statins, and MACE
639STUDY LIMITATIONS. The short follow-up period is
a limitation of our study, restricting the possibility
of performing subgroups analyses adequately such
as a comparison of patients receiving high- versus
moderate- to low-intensity statins. Another limita-
tion is that we did not assess the association of
statins with the incidence of adverse limb out-
comes, which has been reported in secondary pre-
vention of PAD in the REACH (Reduction of
Atherothrombosis for Continued Health) study (46),
and therefore did not measure this outcome in the
follow-up.
CONCLUSIONS
Statin therapy was safely and signiﬁcantly associated
with a reduction in both MACE and total mortality in
study participants without clinical CVD but with
asymptomatic PAD. The absolute reduction was
comparable to that achieved in secondary prevention.
These results support the statin indication in
asymptomatic patients when ABI is #0.95, regardless
of CVD risk assessment.
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